[1. ONISÂI M, VLĂDĂREANU AM, DELCEA C, CIORĂSCU M, BUMBEA H, NICOLESCU A, et al. Perinatal outcome for pregnancies complicated with thrombocytopenia. J Matern Fetal Neonatal Med. 2012; 25(9):1622–6.10.3109/14767058.2011.64824522220678]Search in Google Scholar
[2. CORTELAZZO S1, FINAZZI G, BUELLI M, MOLTENI A, VIERO P, BARBUI T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991; 77(1):31–3.10.1182/blood.V77.1.31.31]Search in Google Scholar
[3. KISTANGURI G, MCCRAE K. Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013; 27(3):495–520.10.1016/j.hoc.2013.03.001367285823714309]Search in Google Scholar
[4. STASI R, NEWLAND AC. ITP: a historical perspective. Br J Haematol. 2011; 153(4):437–450.10.1111/j.1365-2141.2010.08562.x21466538]Search in Google Scholar
[5. COOPER N. State of the art – how I manage immune thrombocytopenia. Br J Haematol. 2017 Apr; 177(1):39–54.10.1111/bjh.1451528295192]Search in Google Scholar
[6. CINES DB, BUSSEL JB, LIEBMAN HA, LUNING PRAK ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113:6511–21.10.1182/blood-2009-01-129155271091319395674]Search in Google Scholar
[7. CINES DB, LIEBMAN H, STASI R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009; 46:S2–14.10.1053/j.seminhematol.2008.12.005268243819245930]Search in Google Scholar
[8. CUKER A, CINES DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2010; 2010:377–84.10.1182/asheducation.V2010.1.377.3643150]Search in Google Scholar
[9. TOLTL LJ, NAZI I, JAFARI R, ARNOLD DM. Piecing together the humoral and cellular mechanisms of immune thrombocytopenia. Semin Thromb Hemost. 2011; 37(6):631–639.10.1055/s-0031-1291373393845522102266]Search in Google Scholar
[10. SEMPLE JW, PROVAN D, GARVEY MB, FREEDMAN J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol. 2010; 17(6):590–595.10.1097/MOH.0b013e32833eaef320739879]Search in Google Scholar
[11. MCMILLAN R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009; 23(6):1163–1175.10.1016/j.hoc.2009.08.008]Search in Google Scholar
[12. NUGENT D, MCMILLAN R, NICHOL JL, SLICHTER SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009; 146(6):585–596.10.1111/j.1365-2141.2009.07717.x]Search in Google Scholar
[13. STASI R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012; 38(5):454–462.10.1055/s-0032-1305780]Search in Google Scholar
[14. BLANCHETTE V, BOLTON-MAGGS P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am. 2010; 24(1):249–273.10.1016/j.hoc.2009.11.004]Search in Google Scholar
[15. BREAKEY VR, BLANCHETTE VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. Semin Thromb Hemost. 2011; 37(7):745–755.10.1055/s-0031-1297165]Search in Google Scholar
[16. LIEBMAN HA. Viral-associated immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2008:212–218.10.1182/asheducation-2008.1.212]Search in Google Scholar
[17. RAJAN SK, ESPINA BM, LIEBMAN HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005; 129(6):818–824.10.1111/j.1365-2141.2005.05542.x]Search in Google Scholar
[18. ZHANG W, NARDI MA, BORKOWSKY W, LI Z, KARPATKIN S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009; 113(17):4086–4093.10.1182/blood-2008-09-181073]Search in Google Scholar
[19. LI Z, NARDI MA, KARPATKIN S. Role of molecular mimicry to HIV-1 peptides in HIV-1 related immunologic thrombocytopenia. Blood. 2005; 106:572–576.10.1182/blood-2005-01-0243]Search in Google Scholar
[20. NARDI M, TOMLINSON S, GRECO MA, KARPATKIN S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell. 2001; 106:551–561.10.1016/S0092-8674(01)00477-9]Search in Google Scholar
[21. LIEBMAN HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009; 46(1 Suppl 2):S33–S36.10.1053/j.seminhematol.2008.12.00419245932]Search in Google Scholar
[22. TEACHEY DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr. 2012; 24(1):1–8.10.1097/MOP.0b013e32834ea739367376322157362]Search in Google Scholar
[23. MICHEL M, CHANET V, DECHARTRES A, MORIN AS, PIETTE JC, CIRASINO L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009; 114(15):3167–3172.10.1182/blood-2009-04-21536819638626]Search in Google Scholar
[24. ARNAL C, PIETTE JC, LEONE J, TAILLAN B, HACHULLA E, ROUDOT-THORAVAL F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002; 29(1):75–83.]Search in Google Scholar
[25. PANITSAS FP, THEODOROPOULOU M, KOURAKLIS A, KARAKANTZA M, THEODOROU GL, ZOUMBOS NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004; 103(7):2645–2647.10.1182/blood-2003-07-226814670926]Search in Google Scholar
[26. SAKAKURA M, WADA H, TAWARA I, NOBORI T, SUGIYAMA T, SAGAWA N, et al. Reduced CD4+CD25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007; 120(2):187–193.10.1016/j.thromres.2006.09.00817067661]Search in Google Scholar
[27. RODEGHIERO F, STASI R, GERNSHEIMER T, MICHEL M, PROVAN D, ARNOLD D, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113(11):2386–93.10.1182/blood-2008-07-16250319005182]Search in Google Scholar
[28. BAO W, BUSSEL JB, HECK S, HE W, KARPOFF M, BOULAD N, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010; 116(22):4639–4645.10.1182/blood-2010-04-281717299611920688957]Search in Google Scholar
[29. STASI R, COOPER N, DEL POETA G, STIPA E, LAURA EVANGELISTA M, ABRUZZESE E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008; 112(4):1147–1150.10.1182/blood-2007-12-12926218375792]Search in Google Scholar
[30. ROARK JH, BUSSEL JB, CINES DB, SIEGEL DL. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002; 100:1388–1398.10.1182/blood.V100.4.1388.h81602001388_1388_1398]Search in Google Scholar
[31. OLSSON B, ANDERSSON PO, JERNAS M, JACOBSSON S, CARLSSON B, CARLSSON LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003; 9(9):1123–1124.10.1038/nm92112937414]Search in Google Scholar
[32. OLSSON B, RIDELL B, CARLSSON L, JACOBSSON S, WADENVIK H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008; 112(4):1078–1084.10.1182/blood-2008-02-13940218519809]Search in Google Scholar
[33. MCMILLAN R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: Assays and epitopes. J Pediatr Hematol Oncol. 2003; 25:S57–S61.10.1097/00043426-200312001-0001314668642]Search in Google Scholar
[34. CINES DB, BLANCHETTE VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346:13–995.10.1056/NEJMra010501]Search in Google Scholar
[35. NAJAOUI A, BAKCHOUL T, STOY J, BEIN G, RUMMEL MJ, SANTOSO S, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012; 88(2):167–174.10.1111/j.1600-0609.2011.01718.x21985182]Search in Google Scholar
[36. NEYLON AJ, SAUNDERS PW, HOWARD MR, PROCTOR SJ, TAYLOR PR. On behalf of the Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Brit J Haematol. 2003; 122:966–974.10.1046/j.1365-2141.2003.04547.x12956768]Search in Google Scholar
[37. PSAILA B, PETROVIC A, PAGE LK, MENELL J, SCHONHOLZ M, BUSSEL JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009; 114(23):4777–4783.10.1182/blood-2009-04-215525278628819767509]Search in Google Scholar
[38. KUHNE T, BERCHTOLD W, MICHAELS LA, WU R, DONATO H, ESPINA B, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011; 96(12):1831–1837.10.3324/haematol.2011.050799323226621880634]Search in Google Scholar
[39. NORGAARD M, JENSEN AO, ENGEBJERG MC, FARKAS DK, THOMSEN RW, CHA S, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood. 2011; 117(13): 3514–3520.10.1182/blood-2010-10-31281921263148]Search in Google Scholar
[40. MITTAL S, BLAYLOCK MG, CULLIGAN DJ, BARKER RN, VICKERS MA. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008; 93(1):151–152.10.3324/haematol.1182218166805]Search in Google Scholar
[41. NEWTON JL, REESE JA, WATSON SI, VESELY SK, BOLTON-MAGGS PH, GEORGE JN, ET AL. Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2011; 86(5):420–429.10.1111/j.1600-0609.2011.01587.x21323737]Search in Google Scholar
[42. KUTER DJ, MATHIAS SD, RUMMEL M, MANDANAS R, GIAGOUNIDIS AA, WANG X, et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012; 87(5):558–561.10.1002/ajh.2316322460421]Search in Google Scholar
[43. MATHIAS SD, BUSSEL JB, GEORGE JN, MCMILLAN R, OKANO GJ, NICHOL JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007; 5:11.10.1186/1477-7525-5-11180805217316442]Search in Google Scholar
[44. ALEDORT LM, HAYWARD CP, CHEN MG, NICHOL JL, BUSSEL J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004; 76(3):205–213.10.1002/ajh.2010415224353]Search in Google Scholar
[45. DIZ-KUCUKKAYA R, HACEHANEFIOGLU A, YENEREL M, TURGUT M, KESKIN H, NALÇACI M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001; 98:1760–1764.10.1182/blood.V98.6.1760]Search in Google Scholar
[46. NEUNERT C, LIM W, CROWTHER M, COHEN A, SOLBERG L, JR, CROWTHER MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190–4207.10.1182/blood-2010-08-30298421325604]Search in Google Scholar
[47. PROVAN D, STASI R, NEWLAND AC, BLANCHETTE VS, BOLTON-MAGGS P, BUSSEL JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115:168–186.10.1182/blood-2009-06-22556519846889]Search in Google Scholar
[48. PEERSCHKE EI, YIN W, GHEBREHIWET B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010; 47(13):2170–2175.10.1016/j.molimm.2010.05.009290432620621693]Search in Google Scholar
[49. NORIS P, KLERSY C, ZECCA M, ARCAINI L, PECCI A, MELAZZINI F, et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost. 2009; 7(12):2131–2136.10.1111/j.1538-7836.2009.03614.x19740094]Search in Google Scholar
[50. BARSAM SJ, PSAILA B, FORESTIER M, PAGE LK, SLOANE PA, GEYER JT, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011; 117(21):5723–5732.10.1182/blood-2010-11-321398311002921389318]Search in Google Scholar
[51. HOUWERZIJL EJ, BLOM NR, VAN DER WANT JJ, ESSELINK MT, KOORNSTRA JJ, SMIT JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004; 103(2):500–506.10.1182/blood-2003-01-027512969975]Search in Google Scholar
[52. MCMILLAN R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009; 23(6):1163–1175.10.1016/j.hoc.2009.08.00819932426]Search in Google Scholar
[53. NURDEN AT, FRESON K, SELIGSOHN U. Inherited platelet disorders Haemophilia. 2012; 18(Suppl 4):154–60.10.1111/j.1365-2516.2012.02856.x22726100]Search in Google Scholar
[54. BALDUINI CL, PECCI A, SAVOIA A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol. 2011; 154(2):161–174.10.1111/j.1365-2141.2011.08716.x21542825]Search in Google Scholar
[55. BERNDT MC, ANDREWS RK. Bernard-Soulier syndrome. Haematologica. 2011; 96(3):355–359.10.3324/haematol.2010.039883304626521357716]Search in Google Scholar
[56. PORTEILJE JEA, WESTENDORP RGJ, KLUIN-NELEMANS HC, BRAND A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97:2549–2554.10.1182/blood.V97.9.254911313240]Search in Google Scholar
[57. MAZZUCCONI MG, FAZI P, BERNASCONI S, DE ROSSI G, LEONE G, GUGLIOTTA L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007; 109:1401–1407.10.1182/blood-2005-12-01522217077333]Search in Google Scholar
[58. CHENG Y, WONG RS, SOO YO, CHUI CH, LAU FY, CHAN NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003; 349:831–836.10.1056/NEJMoa03025412944568]Search in Google Scholar
[59. ZAJA F, BACCARANI M, MAZZA P, BOCCHIA M, GUGLIOTTA L, ZACCARIA A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010; 115(14):2755–2762.10.1182/blood-2009-07-22981520130241]Search in Google Scholar
[60. BAE SH, RYOO H, LEE WS. High dose dexamethasone vs conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial. Blood. 2010; 116.10.1182/blood.V116.21.3687.3687]Search in Google Scholar
[61. LEONTYEV D, KATSMAN Y, BRANCH DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood. 2012; 119(22):5261–5264.10.1182/blood-2012-03-41569522508937]Search in Google Scholar
[62. COOPER N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am. 2009; 23(6):1317–1327.10.1016/j.hoc.2009.09.00219932436]Search in Google Scholar
[63. GAINES AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106(5):1532–1537.10.1182/blood-2004-11-4303]Search in Google Scholar
[64. COOPER N, WOLOWSKI BMR, FODERO EM, NOVOA M, LEBER M, BEER JH, et al. Does treatment with intermittent infusion of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy. Blood. 2002; 99:1922–1927.10.1182/blood.V99.6.1922]Search in Google Scholar
[65. GEORGE JN, KOJOURI K, PERDUE JJ, VESELY SK. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Sem Hematol. 2000; 37:290–298.10.1016/S0037-1963(00)90107-0]Search in Google Scholar
[66. PSAILA B, BUSSEL JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol. 2008; 143(1):16–26.10.1111/j.1365-2141.2008.07275.x18573111]Search in Google Scholar
[67. PATEL VL, MAHEVAS M, LEE SY, STASI R, CUNNINGHAM-RUNDLES S, GODEAU B, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012; 119(25):5989–5995.10.1182/blood-2011-11-393975338301422566601]Search in Google Scholar
[68. PROVAN D, BUTLER T, EVANGELISTA ML, AMADORI S, NEWLAND AC, STASI R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007; 92(12):1695–1698.10.3324/haematol.1170918055995]Search in Google Scholar
[69. STASI R, DEL POETA G, EVANGELISTA ML, COOPER N, AMADORI S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110:2924–2930.10.1182/blood-2007-02-06899917548576]Search in Google Scholar
[70. RODEGHIERO F. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. Eur J Haematol Suppl. 2008; 69:19–26.10.1111/j.1600-0609.2007.01000.x18211569]Search in Google Scholar
[71. MIKHAEL J, NORTHRIDGE K, LINDQUIST K, KESSLER C, DEUSON R, DANESE M. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review. Am J Hematol. 2009; 84(11):743–748.10.1002/ajh.2150119714591]Search in Google Scholar
[72. THOMSEN RW, SCHOONEN WM, FARKAS DK, RIIS A, JACOBSEN J, FRYZEK JP, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med. 2009;151(8): 546–555.10.7326/0003-4819-151-8-200910200-0000819841456]Search in Google Scholar
[73. GHANIMA W, GODEAU B, CINES DB, BUSSEL JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012; 120(5):960–969.10.1182/blood-2011-12-309153]Search in Google Scholar
[74. KUTER DJ, RUMMEL M, BOCCIA R, MACIK BG, PABINGER I, SELLESLAG D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363(20):1889–1899.10.1056/NEJMoa1002625]Search in Google Scholar
[75. STASI R, BOSWORTH J, RHODES E, SHANNON MS, WILLIS F, GORDON-SMITH EC. Thrombopoietic agents. Blood Rev. 2010; 24(4–5):179–190.10.1016/j.blre.2010.04.002]Search in Google Scholar
[76. KUTER DJ. Romiplostim. Cancer Treat Res. 2011; 157:267–288.10.1007/978-1-4419-7073-2_16]Search in Google Scholar
[77. KUTER DJ, BUSSEL JB, LYONS RM, PULLARKAT V, GERNSHEIMER TB, SENECAL FM, ET AL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371(9610): 395–403.10.1016/S0140-6736(08)60203-2]Search in Google Scholar
[78. BUSSEL JB, PINHEIRO MP. Eltrombopag. Cancer Treat Res. 2011; 157:289–303.10.1007/978-1-4419-7073-2_17]Search in Google Scholar
[79. CHENG G, SALEH MN, MARCHER C, VASEY S, MAYER B, AIVADO M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763):393–402.10.1016/S0140-6736(10)60959-2]Search in Google Scholar
[80. SALEH MN, CHENG G, BUSSEL JB, MEYER O, BAILEY CK, ARNING M, et al. Safety and efficacy of extended treatment with Eltrombopag in adults with chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013; 121(3):537–4510.1182/blood-2012-04-42551223169778]Search in Google Scholar
[81. CUKER A, CHIANG EY, CINES DB. Safety of the Thrombopoiesis-stimulating Agents for the Treatment of Immune Thrombocytopenia. Curr Drug Saf. 2010; 5(2):171–181.10.2174/15748861079093619619534637]Search in Google Scholar
[82. IMBACH P, CROWTHER M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011; 365(8):734–741.10.1056/NEJMct101420221864167]Search in Google Scholar
[83. SARPATWARI A, BENNETT D, LOGIE JW, SHUKLA A, BEACH KJ, NEWLAND AC, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95:1167–117510.3324/haematol.2009.018390289504220145266]Search in Google Scholar
[84. JANSSENS A, TARANTINO MD, BIRD R. Final results from a multicenter, international, single arm study evaluating the efficacy and safety of Romiplostim in adults with primary immune thrombocytopenia. Blood 2011; 118.10.1182/blood.V118.21.3279.3279]Search in Google Scholar
[85. BRYNES RK, ORAZI A, VERMA S, BRAINSKY K, BAILEY CK, BAKSHI K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with Eltrombopag-data from the EXTEND study. Blood. 2011; 118.10.1182/blood.V118.21.528.528]Search in Google Scholar
[86. SPAHR JE, RODGERS GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008; 83(2):122–125.10.1002/ajh.2106017874448]Search in Google Scholar
[87. KOJOURI K, VESELY SK, TERRELL D, GEORGE J. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623–2634.10.1182/blood-2004-03-116815217831]Search in Google Scholar
[88. VESELY SK, ERDUE JJ, RIZVI MA, TERRELL D, GEORGE JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Intern Med 2004; 140:112–120.10.7326/0003-4819-140-3-200402030-0001214734334]Search in Google Scholar
[89. KÜHNE T, BLANCHETTE V, BUCHANAN GR, RAMENGHI U, DONATO H, TAMMINGA RY, et al. Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 2007; 49:829–834.10.1002/pbc.2110817171689]Search in Google Scholar
[90. ARNOLD DM, KELTON JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007; 44:S12–S23.10.1053/j.seminhematol.2007.11.00318096468]Search in Google Scholar
[91. GODEAU B, PROVAN D, BUSSEL J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007; 14:535–556.10.1097/MOH.0b013e3282b9748f17934364]Search in Google Scholar